Zenflow Announces $24 Million Financing Round to Fund FDA Filing & Commercial Preparation
November 18, 2024 19:34 ET
|
Zenflow
SOUTH SAN FRANCISCO, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Zenflow, Inc., a medical device company developing a minimally invasive treatment for urinary obstruction caused by enlarged prostate,...
Profound Medical Announces TULSA Reimbursement Raised to Urology APC Level 7 Under CMS Outpatient Prospective Payment System (OPPS) Final Rule for CY2025
November 04, 2024 06:55 ET
|
Profound Medical Corp.
– TULSA to stand above all other covered prostate disease treatment modalities at Urology Level 7 reimbursement – – First-time CPT® code reimbursement for TULSA to be effective...
Profound Medical Appoints Tom Tamberrino as Chief Commercial Officer
October 16, 2024 16:15 ET
|
Profound Medical Corp.
– Mr. Tamberrino and Profound’s CEO, Arun Menawat, previously worked together at NOVADAQ before it was acquired by Stryker in 2017 – – Appointment comes as Profound continues to make final...
Profound Medical to Release Second Quarter 2024 Financial Results on August 8 – Conference Call to Follow
July 18, 2024 16:30 ET
|
Profound Medical Corp.
TORONTO, July 18, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets...
Prostate Health Market Surges Towards USD 83.8 Billion by 2034, Fueled by Advancements in Diagnostic and Treatment Technologies | TMR Report
July 08, 2024 09:58 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Transparency Market Research. Inc. , July 08, 2024 (GLOBE NEWSWIRE) -- The prostate health market (Markt für Prostatagesundheit) was projected to attain US$ 31.9...
Onconetix™ Chief Executive Officer Dr. Neil J. Campbell Issues Letter to Shareholders
December 19, 2023 07:00 ET
|
Onconetix, Inc.
CINCINNATI, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Onconetix, Inc., (Nasdaq: BWV) ("Onconetix" or the “Company”) today issued the following shareholder letter from the Company’s Chief Executive Officer,...
Blue Water Biotech Acquires Proteomedix as Part of Transformation to Commercial Stage Oncology Company; Announces Name Change to Onconetix™
December 18, 2023 07:00 ET
|
Onconetix, Inc.
CINCINNATI, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (Nasdaq: BWV) ("BWB" or the “Company”) today announced the acquisition of Proteomedix AG, a private, commercial-stage...
Blue Water Biotech Appoints Board-Certified Urologist Jay Newmark, M.D., MBA as Chief Medical Officer
April 26, 2023 15:44 ET
|
Blue Water Biotech, Inc.
CINCINNATI, April 26, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”), a biotechnology company spanning multiple sectors, today announced the appointment of Jay...
Blue Water Announces Acquisition of ENTADFI®, an FDA-Approved Benign Prostatic Hyperplasia Asset
April 20, 2023 07:30 ET
|
Blue Water Vaccines Inc.
Acquisition Transforms the Company into a Broader Pharmaceutical Company Spanning Multiple Sectors Company Announces Corporate Name Change to Underscore Broader Focus Company to Host a Conference...
Midwest Institute for Non-Surgical Therapy (MINT) Introduces New Therapy to Treat Men With Enlarged Prostates
October 21, 2022 09:00 ET
|
The Midwest Institute for Nonsurgical Therapy
ST. LOUIS, Oct. 21, 2022 (GLOBE NEWSWIRE) -- Midwest Institute for Non-surgical Therapy (MINT) has introduced a new therapy to treat men with benign prostatic hyperplasia (BPH). The condition, which...